MedPath

Physiological Study to Compare Noninvasive Ventilation (NIV) Masks

Not Applicable
Terminated
Conditions
Sleep-disordered Breathing
Hypercapnia
Interventions
Device: CPAP with Mask A
Device: CPAP with Mask B
Registration Number
NCT04926805
Lead Sponsor
Fisher and Paykel Healthcare
Brief Summary

Noninvasive ventilation (NIV) is an established therapy that delivers positive pressure to the upper airways to provide respiratory support. Two types of NIV can be delivered; continuous positive airway pressure (CPAP) at one continuous pressure and bilevel NIV at two pressures for inhalation and exhalation.

This investigation is designed to physiologically evaluate the performance of a NIV mask, Mask A, compared to a standard NIV mask, Mask B on CPAP therapy.

People with sleep disordered breathing who have chronic hypercapnia, and are already receiving nocturnal CPAP will be recruited. They will receive one night's CPAP therapy on Mask A and 1 night on Mask B in random order. Physiological parameters will be recorded.

Parameters will be recorded during three baselines at the beginning of each evening and throughout the night when participants are asleep. The three baselines are:

1. participant awake with normal breathing (not on CPAP),

2. participant awake and on CPAP, and

3. participant asleep on CPAP in REM-sleep (rapid eye movement sleep).

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Already using overnight CPAP and tolerating the therapy well (over 4 hours use/night)
  • Hypercapnia: venous bicarbonate of 30 milliequivalents of solute per liter (Eq/L) or more, OR transcutaneous carbon dioxide (TcCO2) of 50 millimeters of mercury (mmHg) of more.
  • Provide written informed consent
  • Already use a full (oronasal) face mask for CPAP
  • Willing to have a venous blood sample taken during the pre-screening visit.
Exclusion Criteria
  • Presence of sleep apnea on CPAP:

    • Subjects excluded if they have an apnea-hypopnea index (AHI) of more than 20, or
    • If the AHI has not already decreased by 50 percent or more from pre-CPAP to with CPAP.
  • Forced expiratory volume in 1 second (FEV1) of less than 40 percent of predicted.

  • Forced expiratory volume in 1 second divided by forced vital capacity (FEV1/FVC) less than fifty percent of predicted, at the screening visit.

    • Have poorly controlled asthma or changing asthma symptoms.
    • Nasal obstruction
    • Do not fit Mask A or Mask B
    • Agitation or psychological illness

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Mask ACPAP with Mask AOvernight CPAP using the participant's usual pressure settings and using Mask A. One night only.
Mask BCPAP with Mask BOvernight CPAP using the participant's usual pressure settings and using Mask B. One night only.
Primary Outcome Measures
NameTimeMethod
Transcutaneous carbon dioxide1 day (From baseline to the end of the study night)

The change in transcutaneous carbon dioxide from the 3 different baselines to the transcutaneous carbon dioxide during non-REM sleep on CPAP on the same study night. Three different values will be determined for each mask.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

New Zealand Respiratory and Sleep Institute

🇳🇿

Auckland, New Zealand

© Copyright 2025. All Rights Reserved by MedPath